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a b s t r a c t
Respiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single most important
cause of serious lower respiratory tract infections in young children, yet no highly effective treatment or
vaccine is available. To clarify the potential for an anti-G mAb, 131-2G which has both anti-viral and anti-
inﬂammatory effects, to effectively treat RSV disease, we determined the kinetics of its effect compared
to the effect of the anti-F mAb, 143-6C on disease in mice. Treatment administered three days after RSV
rA2-line19F (r19F) infection showed 131-2G decreased breathing effort, pulmonary mucin levels, weight
loss, and pulmonary inﬂammation earlier and more effectively than treatment with mAb 143-6C. Both
mAbs stopped lung virus replication at day 5 post-infection. These data show that, in mice, anti-G
protein mAb is superior to treating disease during RSV infection than an anti-F protein mAb similar to
Palivizumab. This combination of anti-viral and anti-inﬂammatory activity makes 131-2G a promising
candidate for treating for active human RSV infection.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Respiratory syncytial virus (RSV), a pneumovirus of the family
Paramyxoviridae, is a leading cause of serious lower respiratory
tract disease in infants and young children worldwide (Nair et al.,
2010). Unfortunately, there is still no highly effective therapeutics
or licensed vaccine to prevent RSV disease. Immune prophylaxis,
initially with RSV immune globulin (Anon, 1998; Groothuis et al.,
1993) and later with an RSV anti-F protein neutralizing mono-
clonal antibody (Anon, 1998), was shown to be effective and is
used to prevent complications of infection in high risk infants and
young children (Geevarghese and Simoes, 2012). Good infection
control practices can prevent the risk of nosocomial transmission
in healthcare settings (Siegel et al., 2007); however effective
treatment to address active infection is needed (Krilov, 2011;
Ramilo et al., 2014; Tayyari and Hegele, 2012). Although ribavirin
may be effective in treating RSV disease in bone marrow trans-
plant patients (Waghmare et al., 2013), and siRNA therapy may be
effective in preventing bronchiolitis obliterans in lung transplant
patients (Zamora et al., 2011), effective treatment is not available
for most RSV-infected patients. This lack of success in treating RSV
disease may indicate insufﬁcient anti-viral activity, or possibly the
need to combine anti-viral with anti-inﬂammatory treatment, as
suggested by a study in cotton rats (Ottolini et al., 2002).
RSV encodes 11 proteins, and among them, the F and G surface
proteins induce protective immunity (Collins and Melero, 2011;
Graham, 2011). The F protein induces high titers of neutralizing
antibodies and better cross-protection against different RSV
strains in mice than the G protein (Connors et al., 1991; Olmsted
et al., 1986; Stott et al., 1987). The G protein has a substantial role
in inducing and modulating the host immune response to infec-
tion (Tripp, 2004), and some of the responses appear to contribute
to disease pathogenesis. The G protein has a CX3C chemokine
motif in the central conserved region of the G protein that has
been shown to contribute to some of these activities (Boyoglu-
Barnum et al., 2013; Harcourt et al., 2006; Haynes et al., 2003;
Tripp et al., 2003). The G protein CX3C motif binds to the CX3C
chemokine receptor, CX3CR1, and mimics some activities of the
only known CX3C chemokine, fractalkine (Tripp et al., 2001). This
motif, located between aa 182–186 of the G protein, includes two
of the four evolutionarily conserved cysteines at aa 173, 176, 182,
and 186 which form a cysteine noose structure.
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Monoclonal antibody (mAb) 131-2G (Anderson et al., 1986,
1988) binds to the central conserved region of the G protein,
blocks G protein binding to CX3CR1, and decreases several disease
manifestations in RSV challenged mice including pulmonary
inﬂammation and mucous production, increased airway resistance
after primary infection in mice, and enhanced inﬂammation in
RSV-challenged FI-RSV vaccinated mice (Boyoglu-Barnum et al.,
2013; Haynes et al., 2009; Miao et al., 2009; Radu et al., 2010;
Tripp et al., 2003). Treatment with this mAb also neutralizes virus
in vivo in an Fc dependent fashion (Miao et al., 2009; Radu et al.,
2010), but not in vitro (Anderson et al., 1988). Importantly, 131-2G
F(ab0)2 decreases pulmonary inﬂammation after both primary RSV
challenge or challenge in FI-RSV vaccinated mice without decreas-
ing viral load (Miao et al., 2009; Radu et al., 2010).
We have previously shown that administration of mAb 131-2G
at 3 days postinfection (p.i.) neutralizes virus and decreases
pulmonary inﬂammation by 5 days p.i. (Miao et al., 2009). The
F(ab0)2 form of 131-2G similarly decreased pulmonary inﬂamma-
tion without effecting lung virus titers. Interestingly, 131-2G
decreased pulmonary inﬂammation more effectively than an
anti-F mAb, 143-6C, that reacts at the same antigenic site as
palivizumab and like palivizumab both neutralizes RSV and
inhibits RSV fusion (Anderson et al., 1988; Boyoglu-Barnum
et al., 2014; DeVincenzo et al., 2014). Han et al. (2014) recently
reported that a humanized mAb that reacts at the same antigenic
site as 131-2G also decreases airway reactivity induced by metha-
choline challenge and does this much more effectively than
palivizumab. These data suggest that an anti-G mAb like 131-2G
might be more effective than anti-F neutralizing antibodies in
treating active RSV infection. To clarify the potential for 131-2G-
like antibodies to effectively treat RSV disease, we determined the
kinetics of its effect compared to the effect of the anti-F mAb, 143-
6C on disease in mice. Since airway disease is such an important
component of human RSV disease, we studied the effect of these
mAbs on virus induced airway resistance and mucus production in
mice infected with RSV rA2-line19F (r19F). RSV r19F increases
airway resistance and mucus productions in mice while the more
commonly used RSV A2 strain does not (Boyoglu-Barnum et al.,
2013; Lugo and Nahata, 1993). The results demonstrate that
treatment with the anti-G protein mAb 131-2G can decrease RSV
airway disease more rapidly and effectively than the anti-F protein
mAb 143-6C.
Results
131-2G mAb treatment reduces weight loss earlier than 143-6C
RSV infected mice treated with 131-2G mAb began to promptly
reverse morbidity as determined by weight loss in infected mice
(Fig. 1). On day 5 pi, the weights for 131-2G treated mice were
signiﬁcantly (pr0.05) higher than untreated mice (97.6071.39%
vs 94.5975.84% of pre-infection weight, respectively). The
increased weight in 131-2G treated compared to untreated, RSV
infected mice persisted through day 8 pi though no longer
signiﬁcantly greater than for untreated mice. Mice treated with
143-6C mAb showed less reversal of weight loss with weig-
hts being greater, but not signiﬁcantly (p40.05) greater
than untreated, infected mice at day 5 pi (95.7872.31% vs
94.5975.84% of weight before infection, respectively) (Fig. 1).
131-2G mAb and 143-6C treatment decrease pulmonary virus titer
The effects of treatment with mAbs 131-2G and 143-6C on lung
virus load were determined on days 4–8 pi. In untreated mice,
virus was isolated from the lung through day 6 pi. With mAb 131-
2G, virus was only isolated at 4 days pi (TCID50 log 2.6970.09) at a
titer 2.17 log-fold less than untreated mice. Live virus was not
detected (TCID504 log 2.2471.14 is the limit of detection) at any
day posttreatment in mice treated with mAb 143-6C (Table 1).
The RSV real-time PCR results for lung specimens (3 mice/
group) on days 4–8 pi similarly showed that treatment with both
mAbs decreased virus replication beginning immediately after
treatment with 143-6C being somewhat more effective than 131-
2G, i.e. no infectious virus on day 4 pi (Table 1) and lower CT
values on day 5 pi (Fig. 2).
131-2G mAb treatment reduces pulmonary inﬂammation
The effects of treatment with mAbs 131-2G and 143-6C on
pulmonary inﬂammation based on BAL cells on days 4, 5, 6, 7 and
8 pi showed the peak number of cells (21910375.77103) was on
day 5 pi in untreated, r19F infected mice. Treatment with 131-2G
showed a rapid effect of treatment with a signiﬁcant (po0.05)
decrease in the total BAL cell number compared to untreated mice
for all days after treatment. In contrast, treatment with 143-6C did not
Fig. 1. The effect of treatment of RSV G protein mAb 131-2G or RSV F protein mAb
143-6C on weight change in r19F infected BALB/c mice. BALB/c mice were i.n.
infected with r19F (1106 TCID50) on day 0 and administered 300 mg of anti-G
(131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/group). Data are
mean7SEM. * indicates signiﬁcant increase on the body weight after 131-2G
treatment compared to untreated, infected mice. No signiﬁcant difference was
detected for mAb 143-6C treated compared to untreated, infected mice. Signiﬁ-
cance (pr0.05) was determined by one-way analysis of variance (ANOVA) and
post-hoc Tukey's HSD test. Results are representative of two independent
experiments.
Table 1
The effect of anti-RSV G protein mAb 131-2G and anti-RSV F protein mAb 143-6C
treatments on viral load of BALB/c mice. Viral titer represented as log values.
Groups Day 4 pi Day5 pi Day 6 pi Day 7 pi Day 8 pi
r19F 5.8470.78* 5.2970.66* 3.1470.82* ND ND
r19Fþ143-6C ND ND ND ND ND
r19Fþ131-2G 2.6970.09 ND ND ND ND
r19FþnIgG 5.8970.25 5.3170.129 3.1870.58 ND ND
Mock ND ND ND ND ND
BALB/c mice were infected with r19F (1106 TCID50) on day 0 and administered
300 mg of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼3 mice/
group). Data are mean7SEM. Signiﬁcance (po0.001) was determined by one-way
analysis of variance (ANOVA) and post-hoc Tukey's HSD test. Results are repre-
sentative of two independent experiments. ND: Not detected.
n Signiﬁcant difference on viral load untreated, r19F challenged mice compared
with mAb 131-2G and mAb 143-6C treated mice.
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signiﬁcantly (pZ0.05) decrease BAL cell numbers on day 4 pi, but did
on the remaining days. The decrease in BAL cell numbers after 143-6C
treatment was signiﬁcantly (pr0.05) less than after 131-2G treatment
at all time-points (Fig. 3). There also was substantial difference in the
types of cells in the BAL (Table 2) between the two treatments. On day
4 pi, the greatest difference in cell types between 131-2G and 143-6C
treatment was in B cells, PMNs, and NK cell numbers. By days 5 and
6 pi, the greatest difference between the two treatments was for CD3,
CD4, and CD8 positive cell numbers. For example, on day 4 pi, the
percent decrease compared to untreatedmice for CD3 CD45R/B220þ
cells (B cells) was 11.2% for 131-2G and 1.0% for 143-6C; for CD3 Ly-
6G/Gr-1þ cells (polymorphonuclear cells, PMNs) 78.9% for 131-2G and
9.0% for 143-6C; and for CD49b/integrin alpha 2þ cells (NK cells)
38.8% for 131-2G and 9.3% for 143-6C for CD3. On day 6 pi, the percent
decrease compared to untreated mice for CD3þ cells was 49.1% for
131-2G and 8.7% for 143-6C; for CD4þ cells 46.1% for 131-2G and 6.9%
for 143-6C; and for CD8þ cells 51.3% for 131-2G and 5.39% for 143-6C.
131-2G mAb treatment reduces airway dysfunction earlier than 143-6C
The effects of treatment with mAbs 131-2G and 143-6C on airway
dysfunctionwas assessed by pulsus paradoxus on days 6, 8, 10 and 12
pi. Similar to previous studies (Boyoglu-Barnum et al., 2013; Stokes
et al., 2011), r19F challenged mice had signiﬁcant (pr0.05) increase
in breathing effort compared to mock-infected mice on day 6 pi
which increased through day 8 pi (Fig. 4). Treatment with mAb 131-
2G signiﬁcantly (pr0.001) decreased r19F induced breathing effort
to levels similar to mock-infected mice at all time-points examined.
In contrast, treatment with 143-6C did not decrease RSV r19F
induced breathing effort until 8 days pi and breathing effort was
greater at all time-points compared to 131-2G treated mice (Fig. 4).
On day 8 pi, there was a 67.2175.84% decrease in breathing effort for
131-2G treated compared to untreated, infected mice while 143-6C
treated mice had a 47.0673.81% decrease in breathing effort (Fig. 4).
131-2G mAb treatment reduces pulmonary mucin production earlier
than 143-6C
An increase in airway mucous is one feature of RSV disease in
children (Lugo and Nahata, 1993; Quinn et al., 1985). In this study,
untreated r19F challenged mice when compared to mock chal-
lenged mice showed increased mucous production on days 4–8 pi
with peak increase on day 8 pi (Fig. 5). There was a signiﬁcant
(pr0.001) decrease in Muc5AC protein in the lungs of the mice
treated with 131-2G on days 5, 6, 7 and 8 but only on days 7 and
8 for 143-6C treated mice (Fig. 5).
Differences in pulmonary mucous levels were also evident in
lung histopathology studies by either qualitative measurements
with PAS staining (Fig. 6) or quantitative measurements with
ImageJ analysis (Fig. 7). Stained lung sections showed PAS-
positive cells for untreated, or control mAb treated r19F challenged
mice on days 6, 7 and 8 pi. Mock challenged mice and mAb 131-2G
treated, r19F challenged mice did not show PAS-positive cells at
any time-points while mAb 143-6C treated, r19F challenged mice
showed PAS positive cells on days 6 and 7 pi (Figs. 7 and 8).
Cytokine responses
To evaluate the effect of treatment with 131-2G and 143-6C mAbs
on lung inﬂammation, we determined cytokine and chemokine
levels in lung homogenates. The most notable differences were on
days 5, 6 and 7 pi when lower levels of pro-inﬂammatory and Th2
cytokines were detected in 131-2G treated compared to untreated
r19F infected mice. For these days, mice treated with 143-6C had
slightly lower levels of some pro-inﬂammatory and Th2 cytokines
and chemokines compared to untreated mice, but the decreases
were not statistically signiﬁcant and less than in 131-2G treated mice
(Tables 3A and 3B). Th1-type cytokine levels were lower for 131-2G
treated mice compared to untreated mice on days 4 and 5 pi and
then usually higher for days 6, 7 and 8 pi. In contrast, mice treated
with 143-6C tended to have a Th1-type cytokine response pattern
similar to untreated mice (Table 3C). The lower level of pro-
inﬂammatory cytokines after 131-2G treatment is consistent with
fewer inﬂammatory cells in the lung. Since Th2 cytokines such as IL-
4, IL-13, IL-5 and MCP-1 have been associated with the increased
airway resistance and mucous production (Boyoglu-Barnum et al.,
2013), lower levels of these cytokines in 131-2G treated mice are
consistent with 131-2G treatment decreasing airway resistance and
mucous production in r19F infected mice. The higher level of Th1
cytokines later during infection consistently shifts away from a Th2
type response and is toward a Th1 memory response with 131-2G
treatment previously noted (Boyoglu-Barnum et al., 2014).
Fig. 3. The effect of treatment of RSV G protein mAb 131-2G and RSV F protein mAb
143-6C on BAL cell number in r19F infected BALB/c mice. BALB/c mice were infected
with r19F (1106 TCID50) on day 0 and administered 300 mg of anti-G (131-2G) or
anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/group). Data are mean7SEM.
* indicates signiﬁcant decrease for 131-2G treated compared to untreated, infected
mice; † indicates signiﬁcant decrease in cell number for mAb 143-6C treated
compared to untreated, infected mice; ǂ indicates signiﬁcant decrease in cell
number for 131-2G treated compared to mAb 143-6C treated. Signiﬁcance
(po0.05) was determined by one-way analysis of variance (ANOVA) and post-
hoc Tukey's HSD test. Results are representative of two independent experiments.
Fig. 2. The level of RSV replication in lung tissue was evaluated by real-time RT-
PCR (qRT-PCR) for M gene expression (relative genome level equivalent log PFU/g of
lung tissue). BALB/c mice were i.n. infected with r19F (1106 TCID50) on day 0 and
administered 300 mg of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi
(n¼5 mice/group). Data are mean7SEM. † indicates signiﬁcant decrease for mAbs
131-2G or 143-6C treated compared to untreated, infected mice. Signiﬁcance
(po0.001) was determined by one-way analysis of variance (ANOVA) and post-
hoc Tukey's HSD test.
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Discussion
Respiratory syncytial virus (RSV) is a leading cause of serious
lower respiratory tract disease in infants and young children
worldwide, and may lead to as many as 200,000 deaths and 3–4
million hospitalizations in children o5 years of age each year
(Nair et al., 2010). Though a high priority for vaccine and antiviral
drug development neither a vaccine nor highly effective antiviral
drug is yet available. The focus of RSV anti-viral drug development
has been stopping virus replication. In a recent study of RSV
challenged adults, treatment early in illness with a drug that
blocks RSV fusion was highly effective in decreasing virus replica-
tion and decreasing upper respiratory tract symptoms
(DeVincenzo et al., 2014). It is unknown if this, or other drugs,
will also be effective in treating disease later in the course of
naturally acquired infection. To have a signiﬁcant effect on disease
later during infection, the antiviral drug must control infection and
disease quicker than the host's immune response does. Our data in
mice show that the anti-F mAb 143-6C may stop virus replication
quicker than the anti-G protein mAb 131-2G but 131-2G treats
disease much quicker. The anti-F protein mAb 143-6C used in this
study is a mouse alternative to palivizumab, i.e. it reacts at the
same antigenic site and has similar activities to those of palivizu-
mab (Anderson et al., 1988; Beeler and van Wyke Coelingh, 1989;
Johnson et al., 1997). In humans palivizumab is effective for
prophylaxis of RSV disease in high risk infants but neither it, nor
a more potent mAb derived from palivizumab, has been effective
in treating active RSV infection (Ramilo et al., 2014). Mice treated
with mAb 131-2G 3 days pi with RSV r19F showed a marked
decrease in all measures of disease assessed including weight loss,
the number and type of pulmonary inﬂammatory cells, airway
resistance, and mucus production several days sooner than, mice
treated with 143-6C. This was evident despite 143-6C's slightly
greater effect on virus replication as indicated by pulmonary virus
titer and RSV RNA levels. These ﬁndings support and extend the
ﬁndings described by Han et al. (2014). In that study, RSV-infected
mice treated on 2 day pi with a humanized anti-G mAb similar to
131-2G had signiﬁcantly less methacholine induced airway resis-
tance than untreated mice at days 7–10 pi. These anti-G mAb
treated mice also had a lower number of BAL cell number on day 7
pi. In contrast mice treated on day 2 pi with the anti-F mAb
palivizumab had levels of methancholine induced airway
Table 2
Changes in the characteristics of the BAL cell inﬁltrate after treatment with the anti- G protein mAb 131-2G and the anti-F protein mAb 143-6C.
Days(pi) Phenotype Untreated mAb 131-2G treated mAb 143-6C treated
Mean number cells [103]7SE Mean number cells [103]7SE % Reduction Mean number cells [103]7SE % Reduction
4 CD3 42.0170.17 34.5670.53n 17.7370.93 33.8671.20n 19.3873.18
CD4 22.6870.25 19.9870.19n 11.9271.78 20.4670.80 9.5472.56
CD8 19.3370.42 14.5970.34n 24.5270.14 13.4170.40nn 30.5673.55
B cells 8.7770.41 7.7970.05n 11.1770.04 8.6870.08n 1.0370.20
Macrophage 8.8870.04 4.9370.71n 44.4677.83 6.5670.24nn 26.0372.99
PMNs 9.6770.13 2.0470.71nn 78.9072.11 8.8070.06n 8.9970.34
NK 47.3170.14 28.9471.26nn 38.8272.83 42.9371.22n 9.2772.33
5 CD3 71.2872.66 36.0670.83n 49.3273.06 68.7470.14 3.4873.40
CD4 31.0370.70 15.7970.13nn 49.1170.73 28.6670.26 7.5972.93
CD8 24.8870.05 9.8170.31nn 61.4972.41 24.7870.09 2.8272.64
B cells 12.4570.52 8.1770.07n 36.7873.09 11.3671.00 12.3674.21
Macrophage 17.4370.31 6.9670.24nn 60.0372.09 14.9870.50n 14.0074.40
PMNs 6.9070.35 1.9770.09nn 67.4374.53 6.1170.58n 19.7873.56
NK 71.0473.16 29.3171.43nn 58.6173.85 62.9971.56 11.1376.14
6 CD3 74.8370.79 38.1270.20nn 49.0570.27 68.3072.17 8.7471.93
CD4 39.6670.77 19.3370.06nn 46.0971.37 37.5371.31 6.9172.48
CD8 24.4770.97 13.1970.33nn 51.2670.79 22.7770.60 5.3971.48
B cells 7.3670.09 4.1670.39nn 43.3676.11 6.6170.29 10.1970.77
Macrophage 15.3370.21 10.1970.38n 33.5671.57 10.1370.58n 33.9272.88
PMNs 3.5670.21 2.5470.03n 28.6670.69 2.6570.14n 25.7274.03
NK 73.3573.09 36.0470.23nn 50.7972.39 34.0971.67nn 53.3874.24
7 CD3 76.9471.93 38.7271.20nn 49.6272.82 65.7772.00 14.1270.46
CD4 45.7071.41 23.2570.65n 49.0673.00 40.6971.58 10.9970.71
CD8 25.4874.55 10.6970.64nn 49.6873.76 17.1370.33 19.4770.38
B cells 6.8370.24 5.3070.29nn 45.9974.32 5.9170.48 13.4770.23
Macrophage 15.5870.31 9.4470.27nn 39.3472.95 8.0570.17nn 48.2970.07
PMNs 3.8970.06 2.4770.06nn 36.4670.67 2.5870.06nn 33.5772.46
NK 61.0371.55 36.9874.01nn 46.2670.02 29.3470.97nn 56.8776.08
8 CD3 70.1271.95 40.4971.11nn 42.2670.02 51.8672.11n 26.0470.95
CD4 42.1770.97 24.2570.66nn 42.5070.25 30.7271.22n 27.1771.21
CD8 17.8870.58 12.0870.21n 32.4170.99 14.9970.61n 16.2170.70
B cells 8.4270.20 3.3870.09nn 59.9370.14 4.3470.16nn 48.5270.67
Macrophage 11.6570.01 5.7870.22nn 50.4171.85 5.3870.17nn 53.8171.44
PMNs 3.5270.10 1.4170.06nn 59.9472.92 1.7170.09nn 51.4174.17
NK 51.9571.12 19.7070.37nn 62.0870.10 23.1271.04nn 55.5171.05
BALB/c mice were infected with r19F (1106 TCID50) on day 0 and administered 300 mg of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/group).
Data are the mean total number of BAL cells by subtype at days 4–8 pi per lung: lymphocyte gate, anti-CD3þ (17A2), and anti-CD4þ (GK1.5) CD4 T cells; lymphocyte gate,
CD3þ and anti-CD8þ (53-6.7)-CD8 T cells; CD3-, anti-CD45R/B220þ (RA3-6B2)-B cells; CD3-, anti-CD11bþ (M1/70)-macrophages, dendritic cells, and monocytes; CD3-,
anti-mouse Ly06G/Gr-1 (RB6-8C5)-Polymorphonuclear cells (PMNs); CD3-, anti-mouse CD49b/Integrin alpha2 (DX5)-NK cell. The fold reduction is decrease in the number in
treated relative to untreated mice for the cell type. Results are representative of two independent experiments.
n Signiﬁcant decrease in numbers of untreated compared to mice receiving the indicated treatments (pr0.05, ANOVA).
nn Signiﬁcant decrease in numbers of untreated compared to mice receiving the indicated treatments (pr0.001, ANOVA).
S. Boyoglu-Barnum et al. / Virology 483 (2015) 117–125120
Fig. 6. Mucin production associated with RSV r19F infection and RSV anti-G and F protein mAbs 131-2G and 143-6C treatment. BALB/c mice were infected with mock-
infected tissue culture supernatant (mock) or 1106 TCID50 of r19F and untreated or treated 3 days after challenge with mAbs 131-2G and 143-6C or control immune
globulin (nIgG). The lungs were harvested 4–8 days pi for PAS staining. Reddish-purple color within cells lining bronchioles or alveoli indicates cells that are PAS positive and
contain mucin (n¼3 mice/group). Day 6, ﬁrst day with clear PAS staining, and day 8, last day studied, shown.
Fig. 4. The effect of treatment of RSV G protein mAb 131-2G and RSV F protein mAb
143-6C on breathing effort in r19F infected BALB/c mice. BALB/c mice were infected
with r19F (1106 TCID50) on day 0 and administered 300 mg of anti-G (131-2G) or
anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/group). Breath associated
change in distension of peripheral arteries in microns (breathing effort) was
measured at 6, 8, 10 and 12 days pi. Data are mean7SEM. * indicates signiﬁcant
decrease (pr0.05) for mAbs 131-2G or 143-6C treated compared to untreated,
infected mice; † indicates signiﬁcant decrease (pr0.001) for mAbs 131-2G or 143-
6C treated compared to untreated, infected mice; ǂ indicates signiﬁcant decrease
for 131-2G treated compared to mAb 143-6C treated mice. Signiﬁcance (pr0.001)
was determined by one-way analysis of variance (ANOVA) and post-hoc Tukey's
HSD test. Results are representative of two independent experiments.
Fig. 5. The effect of treatment of RSV G protein mAb 131-2G and RSV F protein mAb
143-6C on muc5AC protein levels in r19F virus infected BALB/c mice. BALB/c mice
were infected with r19F (1106 TCID50) on day 0 and administered 300 mg of anti-
G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/group). The
lungs were harvested 8 days pi and lung homogenates tested for muc5AC levels.
Data are mean7SEM. * indicates signiﬁcant decrease (pr0.05) for mAbs 131-2G or
143-6C treated compared to untreated, infected mice. † indicates signiﬁcant
decrease (pr0.001) for mAbs 131-2G or 143-6C treated compared to untreated,
infected mice; ǂ indicates signiﬁcant decrease (pr0.05) for 131-2G treated
compared to mAb 143-6C treated. Signiﬁcance was determined by one-way
analysis of variance (ANOVA) and post-hoc Tukey's HSD test. Results are repre-
sentative of two independent experiments.
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Fig. 7. Percentage of PAS positive cells in mouse airways. PAS-stained slides were
digitally scanned using a Hamamatsu Nanozoomer 2.0HT slide scanner (Meyer
Instruments, Houston, TX) with a 20 objective and analyzed using ImageJ
software. Fifteen to 20 ﬁelds (20 magniﬁcation) were examined per tissue
section and the percentage of PAS positive cells determined using ImageJ software.
Data are mean7SEM. † indicates signiﬁcant difference (pr0.001) for mAb 131-2G
and mAb 143-6C treated mice compared untreated, r19F infected mice; ǂ indicates
signiﬁcant decrease (pr0.05) for mAb 131-2G treated compared to mAb 143-6C
treated, as determined by one-way analysis of variance (ANOVA) and post-hoc
Tukey's HSD test compare. Results are representative of two independent
experiments.
Table 3A
The effect of anti-G protein mAb 131-2G and anti-F protein 143-6C treatment on
Pro inﬂammatory cytokine/chemokine levels in r19F RSV infected mice
Untreated mAb 131-2G
treated
mAb 143-6C
treated
Days
(pi)
Pro inﬂammatory
Cytokines/
chemokines
pg/gram of
lung
pg/gram of
lung
pg/gram of
lung
4 MIP-1α 20.4573.17 14.6073.46* 18.3372.18
MCP-1 16.0472.08 13.2473.87n 15.7272.45
IL-1α 42.8775.36 25.9674.43nn 27.5373.12nn
IL-1β 4.5772.10 2.8671.83 4.4673.49
IL-6 7.5274.99 5.6674.51 6.7272.64
5 MIP-1α 44.01715.07 19.41715.31nn 46.0073.88
MCP-1 31.76712.64 12.24711.88nn 30.0275.39
IL-1α 109.46741.43 42.7579.84nn 95.58731.70
IL-1β 15.3373.02 2.7972.74nn 11.6476.30
IL-6 13.6075.99 6.5571.52 8.5074.83
6 MIP-1α 47.41713.03 24.0675.51n 33.77712.12
MCP-1 65.17714.55 19.8777.93nn 45.25725.79
IL-1α 96.28726.17 48.3474.21nn 56.24711.26nn
IL-1β 22.38714.11 7.4775.12nn 15.9076.84
IL-6 10.5673.51 6.1070.51 7.6171.02
7 MIP-1α 21.9874.73 25.5578.85 25.9672.24
MCP-1 31.90712.52 20.0276.40n 31.6275.48
IL-1α 42.8177.42 36.05714.80 50.5179.97
IL-1β 10.9073.70 5.3173.57 5.0673.50
IL-6 5.6374.47 ND 1.7871.75
8 MIP-1α 14.3772.47 11.2276.38 12.2575.03
MCP-1 8.0773.78 6.8773.79 8.9474.56
IL-1α 33.5473.11 27.58710.71 30.65710.41
IL-1β ND ND ND
IL-6 2.7571.97 ND ND
BALB/c mice were infected with r19F (1106 TCID50) on day 0 and administered
300 mg of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/
group). The lungs were harvested on the indicated days. The lung homogenates
were tested by luminex multiplex assay. Data are mean7SEM. Results are
representative of two independent experiments.
n Signiﬁcant changes in cytokine concentrations for untreated compared to
mice receiving the indicated treatments (pr0.05, ANOVA).
nn Signiﬁcant changes in cytokine concentrations for untreated compared to
mice receiving the indicated treatments (pr0.001, ANOVA).
Table 3B
The effect of anti-G protein mAb 131-2G and anti-F protein 143-6C treatment on
Th2 type cytokine levels in r19F RSV infected mice.
Untreated mAb 131-2G
treated
mAb 143-6C
treated
Days
(pi)
Th2
cytokines
pg/gram of
lung
pg/gram of lung pg/gram of lung
4 IL-4 15.2173.19 14.3572.61 14.0071.77
IL-5 10.6570.32 4.6770.77n 9.8470.47
IL-13 ND ND ND
5 IL-4 45.14715.54 12.3473.23nn 34.56712.43
IL-5 14.3071.16 2.3471.56nn 6.7172.49
IL-13 ND ND ND
6 IL-4 30.2075.91 12.1173.83n 24.3479.20
IL-5 4.5572.38 1.6870.71 3.0171.45
IL-13 12.8671.98 4.8672.01n 11.9871.68
7 IL-4 19.7473.58 11.3371.60 11.2674.15
IL-5 1.8270.62 0.9270.41 2.0071.16
IL-13 16.8473.32 4.2171.28nn 10.8672.49
8 IL-4 4.6872.75 1.2571.09 2.9972.18
IL-5 ND ND ND
IL-13 28.3475.36 NDnn 5.6871.42nn
BALB/c mice were infected with r19F (1106 TCID50) on day 0 and administered
300 mg of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/
group). The lungs were harvested on the indicated days. The lung homogenates
were tested by luminex multiplex assay. Data are mean7SEM. Results are
representative of two independent experiments.
n Signiﬁcant changes in cytokine concentrations for untreated compared to
mice receiving the indicated treatments (pr0.05, ANOVA).
nn Signiﬁcant changes in cytokine concentrations for untreated compared to
mice receiving the indicated treatments (pr0.001, ANOVA).
Table 3C
The effect of anti-G protein mAb 131-2G and anti-F protein 143-6C treatment on
Th1 type cytokine levels in r19F RSV infected mice.
Untreated mAb 131-2G
treated
mAb 143-6C
treated
Days
(p.i)
Th1
cytokines
pg/gram of lung pg/gram of lung pg/gram of lung
4 MIG 132.39762.18 141.26763.57 122.39769.97
IFN-γ 0.7170.29 0.4970.21 0.5470.17
IP-10 41.75716.07 10.7972.82nn 14.2872.43nn
IL-12 3.4470.37 2.9972.67 2.5971.18
5 MIG 1472.677668.69 203.257185.86nn 507.307367.72nn
IFN-γ 82.04726.35 11.8975.44nn 57.82721.07n
IP-10 218.797105.51 51.59730.15nn 155.49768.46
IL-12 3.4271.40 2.5471.76 2.6270.45
6 MIG 1521.287679.05 2335.7771016.70 697.947388.84nn
IFN-γ 62.88724.23 80.88743.46 28.61717.29nn
IP-10 205.40743.72 232.32777.85 96.85741.80nn
IL-12 4.4472.57 6.5871.16 1.5070.52
7 MIG 537.76734.49 1118.747296.59nn 1069.707496.54nn
IFN-γ 24.2577.83 53.3778.60n 29.2777.53
IP-10 60.77714.30 141.90736.47nn 60.77719.81
IL-12 2.6370.42 5.0271.95 2.3270.62
8 MIG 507.397156.93 408.927230.97 290.847244.74
IFN-γ 7.8071.24 13.8673.38 7.7175.65
IP-10 29.8875.25 53.74713.96n 36.52720.25
IL-12 3.4371.42 4.7371.70 1.8973.56
BALB/c mice were infected with r19F (1106 TCID50) on day 0 and administered
300 mg of anti-G (131-2G) or anti-F (143-6C) protein mAbs on day 3 pi (n¼5 mice/
group). The lungs were harvested on the indicated days. The lung homogenates
were tested by luminex multiplex assay. Data are mean7SEM. Results are
representative of two independent experiments.
n Signiﬁcant changes in cytokine concentrations for untreated compared to
mice receiving the indicated treatments (pr0.05, ANOVA).
nn Signiﬁcant changes in cytokine concentrations for untreated compared to
mice receiving the indicated treatments (pr0.001, ANOVA).
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resistance similar (days 7, 10 pi) or greater (day 14 pi) than
untreated, infected mice. The anti-F mAb treated mice had similar
numbers of BAL cells as untreated infected mice.
We suspect that 131-2G has a more rapid effect on disease
because it binds G and prevents it from inducing host responses
that contribute to disease. In vivo, 131-2G has both an anti-viral
effect and an anti-inﬂammatory effect (Miao et al., 2009; Radu
et al., 2010) and it is likely that the anti-inﬂammatory effect
explains the more rapid effect on disease. Earlier studies show that
RSV G protein can enhance pulmonary inﬂammation and, thus, it
is not surprising that binding G protein might have an anti-
inﬂammatory effect (Andersson et al., 2000; Collarini et al.,
2009; Hashimoto et al., 2004; Kauvar et al., 2010; Miao et al.,
2009; Radu et al., 2010). For example, experiments in mice
challenged with virus lacking G protein or administered the anti-
G protein mAb before or after challenge show that the presence of
the G protein during infection increases weight loss, pulmonary
inﬂammatory cells (including eosinophils in FI-RSV vaccinated
mice), pulmonary mucous production, and breathing effort. This
effect of G may be related to one or more previously described
immune modulatory effects of G. The G protein has been asso-
ciated with suppressing a number of immune responses including
Toll-like receptor (TLR) 3 or 4 activity, induction of IFN-β (Shingai
et al., 2008), the pro inﬂammatory response of lung epithelial cells
(Arnold et al., 2004), lymphoproliferation (Ray et al., 2001), a
number of innate responses including activation of dendritic cells
(Polack et al., 2005; Ray et al., 2001), and type I IFN production by
inducing suppression of cytokine signaling (SOCS) (Oshansky et al.,
2009). It has also been associated with enhancing other immune
responses including cytotoxic T cell responses (Bukreyev et al.,
2008), pulmonary substance P levels (Tripp et al., 2000), and
pulmonary Th2 cytokines.
The mechanism by which the RSV G protein modulates the host
immune response and augments disease is not clear but could be
linked to the CX3C chemokine motif at aa 182–186. This motif
functionally mimics some activities of the CX3C chemokine
fractalkine (FKN) (Tripp et al., 2001). Some effects of the G protein
have previously been linked directly to the G protein–CX3CR1
interaction including enhanced inﬂammation in RSV challenged
FI-RSV vaccinated mice, decreased migration of CX3CR1þ T cells
to the lung of infected mice, and decreased rate of breathing in
mice given the G protein intravenously.
Importantly, as noted in earlier studies binding G with 131-2G F
(ab0)2 has an anti-inﬂammatory effect without decreasing virus
replication (Boyoglu-Barnum et al., 2013; Miao et al., 2009). The
intact mAb used in this study however does neutralize RSV in vivo
(Boyoglu-Barnum et al., 2013; Miao et al., 2009; Radu et al., 2010).
Thus, in the mouse, 131-2G probably effects the course of RSV
disease by both down regulating G induced inﬂammation and
decreasing virus replication. The pulmonary cytokine and chemo-
kine studies are consistent with and suggest some mechanisms
involved in this effect of 131-2G. Treatment with 131-2G decreased
the proinﬂammatory and Th2 cytokine/chemokine levels and
increased Th1 levels signiﬁcantly more effectively than mAb 143-
6C. Binding G presumably deliminated its ability to increase pro-
inﬂammatory and Th2 cytokines and chemokines that likely
contribute to disease. Presence of the RSV G protein during
infection of mice has previously been associated with increase in
Th2 and proinﬂammatory cytokines and chemokines (Haynes et
al., 2003; Maher et al., 2004; Polack et al., 2005; Tripp et al., 1999).
We hypothesize that a human mAb with activity similar to the
mouse mAb 131-2G will be effective in treating human infection.
The fact that 131-2G rapdily decreases the multiple manifestations
of disease in the mouse including two associated with RSV disease
in humans, i.e. airway dysfucntion and increased mucous produc-
tion, more rapidly than 143-6C and has both an antiviral and
antiinﬂammatory effect, gives us hope that a human version of
131-2G maybe effective in treating human infection when other
anti-RSV treatments have not. The fact that binding the G protein
with antibody effectively decreases disease suggests G should also
be considered as a target for anti-RSV drug development.
Materials and methods
Mice
Six-to-eight weeks old, speciﬁc pathogen-free, female BALB/c
mice (Charles River Laboratory, Wilmington, MA) were used in all
experiments. All animal procedures were performed according to
a protocol approved by Emory University (Atlanta, GA) Institu-
tional Animal Care and Use Committee. RSV r19F was generated as
described previously (Boyoglu-Barnum et al., 2013). Animal study
plan is described in Fig. 8.
Quantiﬁcation of lung viral load
Pulmonary viral load was assessed by measuring infectious
virus in homogenized lung tissue. BeadBeater (Biospec Products,
Bartlesville, OK) was used to homogenize the lungs as described
(Boyoglu-Barnum et al., 2013). Virus infectivity titers were deter-
mined by a micro-infectivity assay as previously described
(Anderson et al., 1985). The infectivity titer was calculated using
the Reed and Muench method.
Viral RNA levels were determined by RSV real-time PCR
Total RNA was extracted from homogenized lung tissue using a
Qiagen total-RNA extraction kit (Qiagen, Valencia, CA) according to
the manufacturer's instructions and stored at 80 1C. Quantitative
real-time PCR was performed by using an AgPath-ID one-step
reverse transcription (RT)-PCR kit (Applied Biosystems, Foster City,
CA) and Stratagene3000 detection system (Agilent Technologies,
Santa Clara, CA). Thermal cycling conditions included 10 min at
45 1C, followed by 45 cycles of 15 s at 95 1C and 1 min at 55 1C. The
primers and probes for the RSV matrix (M) gene were (forward
primer, 50-GGC AAA TAT GGA AAC ATA GCT GAA-30; reverse
primer, 50-TCT TTT TCT AGG ACA TTG TAY TGA ACA G-30; probe,
50-6-carboxyﬂuorescein (FAM)-TGT CCG TCT TCT ACG CCC TCG TC-
black hole quencher 1 (BHQ-1)-30). Serial dilutions of known
Plaque Forming Units (PFU) of RSV RNA were used to obtain a
standard curve for quantitative real-time PCR. Threshold cycles
(CT) for each sample were converted to PFU equivalents/ml (PFU/
ml) using the standard curve. Assays were performed for three
different sets of mice.
Fig. 8. Experimental schedule for animal studies. Day indicates day relative to RSV challenge.
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Bronchoalveolar leuckocyte (BAL) specimens
Mice were anesthetized and euthanized by exsanguination
after severing of the left axillary artery. Bronchoalveolar leuck-
ocytes (BAL) were harvested by lavaging the lungs 3 times using
1 mL sterile 1 PBS for each wash. The BAL cells were stained for
extracellular markers using a microculture staining protocol
described by Tripp et al. (1999). Brieﬂy, BAL cells were blocked
in Fc blocker (anti CD16/32) in 1 PBS with 1% bovine serum
albumin for 15 min at 4 1C and then stained for 30 min at 4 1C in
dark with the appropriate combinations of anti-CD3 (17A2) (T
cells), anti-CD4 (GK1.5) (T cells), anti-CD8 (53-6.7) (T cells), anti-
CD45R/B220 (RA3-6B2) (B cells), anti-CD11b (M1/70) (macro-
phages, dendritic cells, and monocytes), anti-mouse Ly06G/Gr-1
(RB6-8C5) (polymorphonuclear cells; PMNs), anti-mouse CD49b/
Integrin alpha2 (DX5) (NK and NK T cells), and mouse isotype
antibody controls (all from eBiosciences, San Diego, CA) diluted in
staining buffer. The distribution and pattern of cell surface
markers were determined for 30,000 lymphocyte-gated events
analyzed on a BD LSRII ﬂow cytometer (BD Biosciences, Mountain
View, CA) and data analyzed using FlowJo software (TreeStar,
Ashland, OR).
Pulse oximetry
Pulsus paradoxus is an abnormally large decrease in systolic
blood pressure and pulse wave amplitude during inspiration and
indicates increased breathing effort. The pulsus paradoxus, or
breathing effort, was determined by breath-associated difference
in distension of vessel walls detected by a rodent pulse oximeter
(MouseOx; Starr Life Sciences Corp., Oakmont, PA) and used as an
indication of airway dysfunction, as described (Boyoglu-Barnum et
al., 2013). Data were analyzed using Microsoft Excel and presented
in microns.
Determination of Muc5AC protein expression
Mucin-5AC protein (Muc5AC) concentration in lung tissues was
assayed with an ELISA kit for mouse Mucin 5 Subtype AC (USCN
Life Science Inc., Wuhan, China), according to the manufacturers
protocol as previously described (Boyoglu-Barnum et al., 2013).
The concentration of Muc5AC in the samples was determined by
comparing the OD of the samples to the standard curve generated
and expressed as fold increase in levels compared to mock-
infected mice.
Histopathology
Lungs were ﬁxed in 10% formalin for 1 h, followed by 70%
ethanol and embedded in parafﬁn blocks. Five-micrometer sec-
tions of lung tissue were deparafﬁnized in xylene, rehydrated
through a graded series of ethanol and stained with periodic acid-
schiff (PAS) (Sigma-Aldrich, St. Louis, MO) to assess intracellular
pulmonary mucin levels. PAS-stained slides were digitally scanned
using a Hamamatsu Nanozoomer 2.0HT slide scanner (Meyer
Instruments, Houston, TX) with a 20 objective and analyzed
using ImageJ software. Fifteen to 20 ﬁelds (20 magniﬁcation)
were examined per tissue section.
Multiplex cytokine analysis
Pulmonary cytokine levels were determined from the cell-free
supernatant of centrifuged lung homogenates using a mouse
cytokine 20-plex panel kit and the Luminex 100/200TM with
xMAPTM technology (Invitrogen, Valencia, CA). The concentration
of each cytokine was determined by comparison to standard curve
according to the manufacturer's instructions. The threshold of
detection was 1.1270.24 pg/ml. Cytokine levels in lung homo-
genates were normalized to the protein (in milligrams) present in
cell-free preparations of lung supernatants as measured by the
BCA assay, according to the manufacturer's protocol (Thermo,
Rockford, IL).
Statistical analyses
Unless otherwise indicated, groups were compared by one-way
analysis of variance (ANOVA) and post-hoc Tukey's HSD test
(pr0.05). pr0.05 was considered statistically signiﬁcant. All
statistical analyses were performed using the statistical package
R (R Developmental Core Team 2012). Data are shown as
mean7SEM.
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